Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C et al (2020) Sorafenib Maintenance after allogeneic hematopoietic stem cell transplantation for Acute myeloid leukemia with FLT3–Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol 38(26):2993–3002

Article  PubMed  Google Scholar 

Brose MS, Frenette CT, Keefe SM, Stein SM (2014) Management of Sorafenib-related adverse events: a clinician’s perspective. Semin Oncol 41:S1–16

Article  PubMed  Google Scholar 

Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J et al (2011) Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract off Publ Int Soc Oncol Pharm Pract 17(3):197–202

Article  CAS  Google Scholar 

Ostwal V, Gupta T, Chopra S, Lewis S, Goel M, Patkar S et al (2017) Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma. South Asian J Cancer 6(4):144–146

Article  PubMed  PubMed Central  Google Scholar 

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245

Article  CAS  PubMed  Google Scholar